Document is current

Article History

Received: 30 January 2025

Accepted: 4 March 2025

First Online: 23 March 2025

Declarations

:

: Patrick Vermersch received fees for consultancy, advisory board and scientific meetings from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Roche, Imcyse, AB Science, Janssen, Ad Scientiam and BMS, and research support. from Novartis, Sanofi-Genzyme, Roche and Merck. Xavier Moisset received financial support from Allergan-Abbvie, Aptis Pharma, Biogen, BMS-Celgène, Grünenthal, Lilly, Lundbeck, Teva, Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA, Novartis, Orion, Pfizer, Roche, and Sanofi-Genzyme and non-financial support from SOS Oxygène unrelated to the current work. Jérôme de Sèze received fees for consultancy, advisory board and scientific meetings from Novartis, Biogen, Sanofi, Roche, Janssen, Merck Santé S.A.S, Lyon, France, an affiliate of Merck KGaA, Alexion, CSL Behring, Horizon Therapeutics, LFB, Sandoz, and Pfizer. Baptiste Roux and Anais Lecomte are employees of Société Fast4, Montpellier, France. Laura Luciani is an employee of Merck Santé S.A.S, Lyon, France, an affiliate of Merck KGaA. Martine Paret is an employee of Merck Serono S.A.S, Lyon, France, an affiliate of Merck KGaA.

: This study used fictional cases and does not fall within the scope of Articles L.1121–1 and following of the French Public Health Code. Given the nature of the study and the absence of real patient data, the protocol did not require submission to an Institutional Review Board (IRB) or Ethics Committees for approval. Therefore, IRB approval was not required. All participants were informed of the study objectives during recruitment phase. This communication was integral to ensuring that participants understood the purpose and significance of the study. Also, participants were made aware at this time that the results of the study would be published. Participants agreed to participate by providing verbal consent during the recruitment phase and were informed that they could withdraw from the study at any time without any consequences, ensuring their autonomy and comfort throughout the process. The independence of participants was verified as they completed the questionnaire autonomously on their personal devices, including phones, tablets, or computers, thus ensuring that their responses were not influenced by external factors. The protection of individuals’ data was maintained rigorously in accordance with the guidelines specified in the Information Security and Privacy Policy (ISSP). Detailed information regarding these protocols can be provided upon request.